MedTrace Logo

The Sympara VIBE Study for Hypertension

NCT02250495 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2015-09-14

No results posted yet for this study

Summary

The purpose of the VIBE study is to evaluate the efficacy and safety of the Sympara Therapeutic System in the treatment of hypertension

Conditions

Interventions

DEVICE

Sympara Therapeutic System

Sympara Therapeutic System as a non-invasive, fully reversible alternative for the treatment of hypertension

Sponsors & Collaborators

  • Sympara Medical, Inc.

    lead INDUSTRY

Principal Investigators

  • Ian Meredith, AM, PhD · Monash Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-12-31
Completion
2016-01-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02250495 on ClinicalTrials.gov